씨젠

096530KOSDAQ의료용품 및 기타 의약 관련제품 제조업

61.9 / 100

Reference Date: 2026-06-10

Financial Score19.0 / 40

News Sentiment20.9 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 21.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Seegene is a molecular diagnostics specialist established in 2000, leveraging DNA/RNA analysis to detect disease causes, with 91% of its revenue from exports globally. The company utilizes its proprietary Syndromic qPCR technology and 19 patents to develop multiplex diagnostic products, and is expanding AI-driven diagnostic reagent development through collaborations with Microsoft and Springer Nature.

Number of Employees

822people

Average Salary

95.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

31.48Industry Average 19.191.5Point

1.6x industry avg (risky)

PBR

1.50Industry Average 1.302.5Point

Higher than industry avg (caution)

ROE

4.82Industry Average -4.893.5Point

Well below industry avg

Debt Ratio

4.85Industry Average 6.865.0Point

Lower than industry avg (good)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲177.4% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.0% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 7Neutral 0Negative 0Average Sentiment Score 83.6

Positive
씨젠, 유럽 시장에 항생제 내성 진단 신제품 출시
씨젠의 유럽 IVDR 준수 항생제 내성 진단 신제품 출시로 유럽 시장 진출 가속화.
Positive
씨젠, 다제내성균 검출 신제품 유럽 출시…항생제 내성 진단 강화
씨젠의 다제내성균 신제품 유럽 출시로 항생제 내성 진단 분야에서의 기술 리더십 강화 및 시장 확장 기대.
Positive
씨젠, 다세내성균 검출 신제품 'Allplex MDRO Assay' ...
씨젠의 신규 다제내성균 검출 제품 출시로 유럽 시장 진출 확대 및 감염 관리 지원 강화.

Detailed Momentum

52-week position5.0Point

52w mid range (55%)

Current 29,200Won52-week high 35,15052-week low 21,850

1-month return6.0Point

1m +21.67% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral자기주식처분결과보고서2026-05-21
Neutral분기보고서 (2026.03)2026-05-15
Neutral[기재정정]사업보고서 (2024.12)2026-05-15